Patent Asset Index for Alzheimer’s and Parkinson’s patents

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

The Patent Asset Index™ trend of patents for nervous system disorder drugs reveals that the quality of Pfizer’s patents in this field has been dropping steadily since 2005. Their R&D expenditures simply did not pay off.

In contrast, the patent strength of Roche’s portfolio in the same field is rising steadily.

Related Content

Protected: World IP Day 2019 We look at how sports businesses use patents and designs to foster the development of new sports technologies, materials, training, and equipment to h...
The Top 20 Most Innovative Chinese Universities Today, LexisNexis published a ranking of China’s top 20 most innovative universities based on their patent assets. Analysts at LexisNexis have identif...
The Transformation into the New Takeda In 2011 faced with “the impending loss of patent protection on certain leading products”, the Takeda Pharmaceutical Company unveiled its mid-term ...

By continuing to use the site, you agree to the use of cookies. Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close